Authors:
Sara Cavallini Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Search for other papers by Sara Cavallini in
Current site
Google Scholar
PubMed
Close
,
Ilaria Unali Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Search for other papers by Ilaria Unali in
Current site
Google Scholar
PubMed
Close
,
Anna Bertoncelli Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Search for other papers by Anna Bertoncelli in
Current site
Google Scholar
PubMed
Close
,
Riccardo Cecchetto Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Search for other papers by Riccardo Cecchetto in
Current site
Google Scholar
PubMed
Close
, and
Annarita Mazzariol Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Search for other papers by Annarita Mazzariol in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0003-2729-1007
Open access

Abstract

This study focused on Klebsiella pneumoniae isolates that were resistant or had low susceptibility to a combination of ceftazidime/avibactam. We aimed to investigate the mechanisms underlying this resistance. A total of 24 multi-drug resistant isolates of K. pneumoniae were included in the study. The phenotypic determination of carbapenemase presence was based on the CARBA NP test. NG-Test CARBA 5 was also performed, and it showed KPC production in 22 out 24 strains. The molecular characterisation of bla KPC carbapenemase gene, ESBL genes (bla CTX-M , bla TEM , and bla SHV ) and porin genes ompK35/36 was performed using the PCR. Finally, ILLUMINA sequencing was performed to determine the presence of genetic mutations.

Various types of mutations in the KPC sequence, leading to ceftazidime/avibactam resistance, were detected in the analysed resistant strains. We observed that KPC-31 harboured the D179Y mutation, the deletion of the amino acids 167–168, and the mutation of T243M associated with ceftazidime/avibactam resistance. The isolates that did not present carbapenemase alterations were found to have other mechanisms such as mutations in the porins. The mutations both on the KPC-3 enzyme and in the porins confirmed, that diverse mechanisms confer resistance to ceftazidime/avibactam in K. pneumoniae.

Abstract

This study focused on Klebsiella pneumoniae isolates that were resistant or had low susceptibility to a combination of ceftazidime/avibactam. We aimed to investigate the mechanisms underlying this resistance. A total of 24 multi-drug resistant isolates of K. pneumoniae were included in the study. The phenotypic determination of carbapenemase presence was based on the CARBA NP test. NG-Test CARBA 5 was also performed, and it showed KPC production in 22 out 24 strains. The molecular characterisation of bla KPC carbapenemase gene, ESBL genes (bla CTX-M , bla TEM , and bla SHV ) and porin genes ompK35/36 was performed using the PCR. Finally, ILLUMINA sequencing was performed to determine the presence of genetic mutations.

Various types of mutations in the KPC sequence, leading to ceftazidime/avibactam resistance, were detected in the analysed resistant strains. We observed that KPC-31 harboured the D179Y mutation, the deletion of the amino acids 167–168, and the mutation of T243M associated with ceftazidime/avibactam resistance. The isolates that did not present carbapenemase alterations were found to have other mechanisms such as mutations in the porins. The mutations both on the KPC-3 enzyme and in the porins confirmed, that diverse mechanisms confer resistance to ceftazidime/avibactam in K. pneumoniae.

Introduction

During the past decade, carbapenemase-producing Enterobacteriaceae (CPE) have spread worldwide. The initial clinical studies demonstrated that ceftazidime/avibactam is effective for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae (CRE). However, the emergence of ceftazidime/avibactam resistance in CPE has recently been reported [1]. Mortality rates among patients with serious CRE infections are as high as 70% [2]. The carbapenem-resistant Klebsiella pneumoniae strain is associated with high morbidity and mortality and is one of the most serious clinical threats to human health [3]. The most common determinants of carbapenem resistance are the KPC-2 and KPC-3 enzyme variants [2]. Recent studies identified the presence of mutations such as D179Y or plasmid-borne bla KPC-3 , resulting in an impact on ceftazidime/avibactam resistance and causing comparable reductions in meropenem MICs [2]. An additional mutation reported in the bla KPC3 gene is the deletion of six nucleotides in the position 498–503, resulting in a mutant variant with the deletion of glutamic acid and leucine at position 167 and 168 [4]. This study aimed to investigate the resistance mechanisms underlying ceftazidime/avibactam resistant strains isolated in same hospital setting.

Materials and methods

Strains

Twenty-four K. pneumoniae strains that were resistant to or showed low susceptibility to ceftazidime/avibactam and showed resistance to carbapenems were included in the study. The strains were isolated from various infection sites during routine clinical analyses from 2018 to 2020.

Antimicrobial susceptibility

Antimicrobial susceptibility testing was performed using the broth microdiluition method. The antibiotics tested in this study were cefotaxime, ceftazidime, cefepime, aztreonam, imipenem, meropenem, ertapenem, colistin, and the new drug combination ceftazidime/avibactam. An ETEST was performed to confirm the MIC values of ceftazidime/avibactam resistant strains. The results were interpreted following the last EUCAST clinical breakpoint guideline (https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf).

Detection of beta-lactamases

The CARBA NP test [5] is used for the rapid detection of carbapenemase production in Enterobacterales. The NG-Test CARBA 5 (NG Biotech, Guipry, France) has been used for the rapid detection of the five most widespread carbapenemase families: KPC, NDM, VIM, IMP, and OXA-48-like enzymes.

The molecular characterisation of the carbapenemase gene bla KPC [6] and the ESBL genes (bla CTX-M , bla TEM, and bla SHV ) [7] was performed via PCR.

The Porin ompK35 and ompK36 genes were detected using the following primers: ompK35 fw: CGCAATATTCTGGCAGTGGT, ompK35rv: GAACTGGTAAACGATACCCACG, ompK36fw: AGTTAAAGTACTGTCCCTCCTGG ompK36rv: TAGAACTGGTAAACCAGGCCC, that we designed for this study. The PCR conditions that we have set up were: 95 °C × 60 s, 54 °C × 60 s, 72 °C × 90 s for 30 cycles for ompK35, while the annealing temperature was 55 °C in the case of ompK36 gene detection.

The PCR products were purified using a QIAquick PCR purification Kit (Qiagen, Germany) and then sequenced by Eurofins Genomics (Ebersberg, Germany). The derived sequences were analysed using the Basic Local Alignment Search Tool (BLAST) on the NCBI website to investigate the presence of mutations in the ESBL, carbapenemase, and porin genes that could explain the ceftazidime/avibactam resistance.

The molecular function, the active and substrate-binding sites, and the interactions were analysed by searching for the identified protein in UniProt. The Chimera 1.12 programme was used for the interactive visualisation and analysis of the molecular structures and associated data as well as the characterisation of the mutations.

Results and discussion

The MIC values for the 24 strains are reported in Table 1. All strains were observed to be resistant to cephalosporins and aztreonam. All 24 strains were resistant to at least one of three tested carbapenem antibiotics, i.e. imipenem, meropenem, and ertapenem. This resistance may be explained by the fact that all strains harboured the bla KPC gene. A total of 19 of the 24 analysed strains were positive in the CARBA NP test. Moreover, the NG-Test CARBA 5 showed the production of KPC enzymes in 22 of the 24 strains.

Table 1.

Antimicrobial susceptibility of the strains under study selected to be resistant or with low level of susceptibility to ceftazidime/avibactam

strains CTX CAZ FEP ATM IPM MEM ETP COL CAZ-AVI
920 64 >128 64 >128 32 64 >128 0.125 2
939 128 >128 128 >128 128 >128 <128 0.125 4
968 >128 >128 64 >128 64 128 >128 0.125 4
989 32 >128 128 32 0.5 2 32 0.125 >128
1009 4 >128 16 4 0.25 2 8 0.125 32
1209 16 >128 128 >128 16 16 32 0.125 64
1425 4 >128 16 4 0.25 4 16 8 64
1765 >128 >128 >128 >128 64 >128 >128 0.125 32
1764 >128 >128 >128 >128 32 128 >128 16 16
1767 >128 >128 >128 >128 128 >128 >128 0.125 16
1818 >128 >128 >128 >128 16 128 >128 0.125 16
1827 >128 >128 >128 >128 16 32 16 0.25 4
1546 >128 >128 >128 >128 16 16 32 0.125 8
1572 128 128 64 >128 4 8 32 0.125 2
1658 32 >128 128 >128 64 64 128 0.125 4
1714 >128 >128 >128 >128 8 16 16 0.25 8
1740 >128 >128 >128 >128 16 128 >128 0.25 16
1741 >128 >128 128 >128 8 8 16 0.125 8
1782 128 >128 >128 >128 128 128 >128 0.25 8
1795 64 <128 128 >128 16 64 >128 0.25 4
1822 32 >128 32 >128 4 8 8 0.25 2
1872 >128 >128 128 >128 8 8 16 0.25 8
1896 128 >128 >128 >128 4 >128 >128 0.25 32
2543 16 >128 128 32 0.5 2 16 0.125 64

CTX: cefotaxime, CAZ: ceftazidime, FEP: cefepime, ATM: aztreonam, IPM: imipenem, MEM: meropenem, ETP: ertapenem, COL: colistin, CAZ-AVI: ceftazidime/avibactam.

Table 2 presents the molecular and phenotypic characteristics of the strains under study. All 24 of the analysed strains harboured the bla SHV gene, 21 strains harboured the bla TEM gene and 18 strains harboured the bla CTX-M gene (9 of which harboured the bla CTX-M25 gene and 9 harboured the ba CTX-M1 gene). None of the strains harboured carbapenemases except for KPC.

Table 2.

Genetic and phenotypic characteristics related to carbapenemases, ESBL and porins for the strains under study

strain Carbapenemase ESBL Porins MIC (µg ml−1)
CarbaNP Carba5 Gene Mutation Gene Mutation ompK35 ompK36 Mutation Ceftazidime/avibactam
920 + KPC KPC3 no SHV, TEM, CTX-M25 no + + no 2
939 + KPC KPC3 no SHV11,TEM, CTX-M25 no + + no 4
968 + KPC KPC3 no SHV11,TEM no + + no 4
989 KPC31 D179Y SHV, TEM no nd nd \ >128
1009 KPC KPC3 Deletion of 167–168 aa SHV, TEM, CTX-M25 no nd nd \ 32
1209 KPC KPC3 T243M SHV no nd nd \ 64
1425 KPC KPC3 Deletion of 167–168 aa SHV, TEM, CTX-M25 no nd nd \ 64
1765 + KPC KPC3 no SHV, TEM, CTX-M25 no + + Non functional ompK35 32
1764 + KPC KPC3 no SHV, TEM, CTX-M1 no + + Non functional ompK35 and mutated ompK36 (S147A, T154S, N189S, N190D, N272D, V291L) 16
1767 + KPC KPC3 no SHV, TEM, no + + Non functional ompK35 16
1818 + KPC KPC3 no SHV, TEM, CTX-M1 no + + Non functional ompK35 and ompK36 mutated from 349 to 359 aa 16
1827 + KPC KPC3 no SHV1, CTX-M1 no + + no 4
1546 + KPC KPC3 no SHV1, TEM, CTXM-1 no + Non functional ompK35 8
1572 + KPC KPC2 no SHV1, TEM, CTX-M1 no + + no 2
1658 + KPC KPC3 no SHV11, TEM, CTX-M25 no + + no 4
1714 + KPC KPC3 no SHV1, TEM, CTX-M1 no + Non functional ompK35 8
1740 + KPC KPC3 no SHV, TEM, CTX-M1 no + Non functional ompK35 16
1741 + KPC KPC3 no SHV1, TEM, CTX-M1 no + + Non functional ompK35 and mutated ompK36 (guanine insertion in position 448) 8
1782 + KPC KPC3 no SHV11, TEM, CTX-M25 no + + ompK35 mutated from 302 to 327 aa 8
1795 + KPC KPC3 no SHV11, CTX-M25 no + + no 4
1822 + KPC KPC3 no SHV33, TEM no + + no 2
1872 + KPC KPC3 no SHV, TEM, CTX-M1 no \ 8
1896 + KPC KPC3 no SHV, TEM, CTX-M25 no + no 32
2543 KPC31 D179Y SHV, TEM no nd nd \ 64

Nd = Not determined.

\ = Not examined.

For all the strains, the bla KPC gene was sequenced through ILLUMINA analysis. All KPC variants resulted in KPC-3 except the AMP 989 and AMP 2543 strains which presented the KPC-31 variant and the AMP 1572 strain which presented the KPC-2 variant.

The strains harbouring the KPC31 variant, as reported by Giani et al. [8], showed a negative result in the NG-Test CARBA 5, which was not capable of detecting this variant. KPC-31 is a D179Y variant of KPC-3. Moreover, it significantly reduces ceftazidime/avibactam susceptibility and typically behaves like ESBL. The mutation (D179Y) is relevant because the amino acids 163–179 include the Ω-loop that surrounds the active site of KPC [9, 10]. This mutation explains the inability of the KPC enzyme to hydrolyse the antibiotic imipenem in the CARBA NP test and confirms the hypothesis that the KPC enzyme is faulty. Furthermore, the mutation may explain the resistance of the strain to ceftazidime/avibactam because avibactam is unable to bind the KPC enzyme due to the mutation.

Unlike the previous case, the NG-Test CARBA 5 was positive for the AMP 1209 isolate, which indicates that the protein is expressed. However, the CARBA NP test was negative, thus, the protein does not function correctly. Through ILLUMINA sequencing, the presence of KPC-3 was highlighted and, in particular, was detected with the T243M mutation.

The T243M mutation observed in the AMP 1209 strain is relevant because the amino acids 240–243 are close to the hinge-loop that surrounds the active site of KPC [9]. Therefore, a similar situation to the previous case was present. This aminoacidic substitution may explain the negative result obtained in the CARBA NP test and may justify the resistance of the strain to ceftazidime/avibactam.

The analysis of AMP 1009 and AMP 1425 showed the presence of the KPC-3 variant. A mutation in the bla KPC gene was confirmed in both strains and, in particular, a deletion of two amino acids (six nucleotides) at the position 167–168 in the KPC sequence was observed. This mutation affects the proton acceptor active site located at position 167, which corresponds to one of the two amino acids deleted. The UniProt analysis of the carbapenem-hydrolysing β-lactamase KPC showed that the proton acceptor active site, composed of a glutamic acid (LDRWELELNS), is located at position 167, precisely at the site of the deletion [6].

All the strains showed a KPC enzyme mutation at the Ω-loop level. Substitutions in the KPC Ω-loop (amino acid positions 165–179) enhance the affinity for ceftazidime, which is postulated to prevent the subsequent binding of avibactam [9].

Omp35 and Omp36 allow the diffusion of avibactam across the outer membrane [11]. Porin research was performed on the isolates that were considered to be resistant according to the EUCAST clinical breakpoint, as well as the isolates that showed an MIC value of 8 μg ml−1 and did not have mutations in the bla KPC gene.

The ILLUMINA sequencing analysis showed that at least one of the two porin genes for each strain was mutated or deleted. The mutation or deletion of the ompK35/36 genes resulted in a significant increase in the MIC value of CAZ-AVI in K. pneumoniae [12]. The AMP 1896 strain did not present mutations in the ompK36 gene, and PCR analysis showed negative results for the ompK35 gene. The remaining strains showed mutations in at least one of the two porins (OmpK35 and OmpK36). AMP 1546 and AMP 1714 carried the non-functional OmpK35 porin and AMP 1741 carried a non-functional OmpK35 porin in addition to a mutated ompK36 gene provided by a guanine insertion at position 448.

AMP 1782 showed a mutated OmpK35 porin from the amino acids 302 to 327. Moreover, the AMP 1872 PCR analysis result was negative for the ompK35 and ompK36 genes.

The strains that showed a ceftazidime/avibactam MIC value between 2 μg ml−1 and 8 μg ml−1 were considered for ESBL analysis. In particular, the bla SHV genes were sequenced to detect mutation, as reported by Marisa et al. [12]; however, no mutations were detected. The strains with ceftazidime/avibactam MIC values between 2 μg ml−1 and 4 μg ml−1 did not show the onset of resistance mechanisms. It should be noted that the ceftazidime/avibactam EUCAST clinical breakpoint was 8 μg ml−1.

Conclusions

The ceftazidime/avibactam resistance in this group of strains could not be attributed to a single mechanism; therefore, it does not seem to be clonal. With the increased use of ceftazidime/avibactam, it is expected that resistance will continue to emerge and plasmids carrying mutant genes may be disseminated via horizontal gene transfer [13]. Ceftazidime/avibactam resistance is an increasing phenomenon that must be monitored, and the strains that show resistance must be constantly examined to identify the mechanism underlying the resistance.

Conflict of interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

  • 1.

    Gaibani P , Campoli C , Lewis RE , Volpe SL , Scaltriti E , Giannella M , et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 2018; 73: 15251529.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Shields RK , Chen L , Cheng S , Chavda KD , Press EG , Snyder A , et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2017 Feb 23; 61(3): e0209716.

    • Search Google Scholar
    • Export Citation
  • 3.

    Li D , Liao W , Huang H , Du F , Wei D , Mei Y , et al. Emergence of Hypervirulent Ceftazidime/Avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Res 2020; 13: 26732680.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Antinori E , Unali I , Bertoncelli A , Mazzariol A . Klebsiella pneumoniae KPC producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene. Clin Microbioland Infect 2020; 66: 946e1e3.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Nordmann P , Poirel L , Dortet L . Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2012; 18: 15031507.

  • 6.

    Mazzariol A , Lo Cascio G , Ballarini P , Ligozzi M , Soldani F , Fontana R , et al. Rapid molecular technique analysis of a KPC-3-producing Klebsiella pneumoniae outbreak in an Italian surgery unit. J Chemother 2012 Apr; 24(2): 9396.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Dallenne C , Da Costa A , Decre D , Favier C , Arlet G . Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 490495.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Antonelli A , Giani T , Di Pilato V , Riccobono E , Perriello G , Mencacci A , et al. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother 2019; 74: 24642466.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Winkler ML , Papp-Wallace KM , Bonomo RA . Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother 2015; 70: 2279.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Haidar G , Clancy CJ , Shields RK , Hao B , Cheng S , Nguyena MH . Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2017;61:16.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Wang Y , Wang J , Wang W , Cai Y . Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Res 2019; 135.

  • 12.

    Winkler ML , Papp-Wallace KM , Taracila M , Bonomo RA . Avibactam and inhibitor-resistant SHV β-lactamases. Antimicrob Agents Chemother 2015; 59: 3700-3709.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Rozwandowicz M , Brouer MSM , Fischer J , Wagenaar JA , Gonzalez-Zorn B , Guerra B , et al. Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. J Antimicrob Chemother 2018; 73: 11211137.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 1.

    Gaibani P , Campoli C , Lewis RE , Volpe SL , Scaltriti E , Giannella M , et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 2018; 73: 15251529.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Shields RK , Chen L , Cheng S , Chavda KD , Press EG , Snyder A , et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2017 Feb 23; 61(3): e0209716.

    • Search Google Scholar
    • Export Citation
  • 3.

    Li D , Liao W , Huang H , Du F , Wei D , Mei Y , et al. Emergence of Hypervirulent Ceftazidime/Avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Res 2020; 13: 26732680.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Antinori E , Unali I , Bertoncelli A , Mazzariol A . Klebsiella pneumoniae KPC producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene. Clin Microbioland Infect 2020; 66: 946e1e3.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Nordmann P , Poirel L , Dortet L . Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2012; 18: 15031507.

  • 6.

    Mazzariol A , Lo Cascio G , Ballarini P , Ligozzi M , Soldani F , Fontana R , et al. Rapid molecular technique analysis of a KPC-3-producing Klebsiella pneumoniae outbreak in an Italian surgery unit. J Chemother 2012 Apr; 24(2): 9396.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Dallenne C , Da Costa A , Decre D , Favier C , Arlet G . Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 490495.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Antonelli A , Giani T , Di Pilato V , Riccobono E , Perriello G , Mencacci A , et al. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother 2019; 74: 24642466.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Winkler ML , Papp-Wallace KM , Bonomo RA . Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother 2015; 70: 2279.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Haidar G , Clancy CJ , Shields RK , Hao B , Cheng S , Nguyena MH . Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2017;61:16.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Wang Y , Wang J , Wang W , Cai Y . Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Res 2019; 135.

  • 12.

    Winkler ML , Papp-Wallace KM , Taracila M , Bonomo RA . Avibactam and inhibitor-resistant SHV β-lactamases. Antimicrob Agents Chemother 2015; 59: 3700-3709.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Rozwandowicz M , Brouer MSM , Fischer J , Wagenaar JA , Gonzalez-Zorn B , Guerra B , et al. Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. J Antimicrob Chemother 2018; 73: 11211137.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2023  
Web of Science  
Journal Impact Factor 1.3
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.31
Scopus  
CiteScore 2.3
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.389
Scimago  
SJR index 0.308
SJR Q rank Q3

Acta Microbiologica et Immunologica Hungarica
Publication Model Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article (only for OA publications)
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 772 EUR / 848 USD
Print + online subscription: 860 EUR / 944 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2024 0 40 18
Sep 2024 0 44 18
Oct 2024 0 153 31
Nov 2024 0 67 121
Dec 2024 0 47 30
Jan 2025 0 72 14
Feb 2025 0 25 3